MyStart Health vs Gala Health: Tirzepatide Price and Terms Compared

MyStart Health and Gala Health at a glance

How to decide

If you expect to maintain at 10 mg or above, weight the higher tiers heavily — that is where you will spend most of the year. If your prescriber expects to hold you at 5 mg, the lower tiers matter more and the ranking may reverse.

Beyond price, the questions that actually differentiate programs are: is the compounding pharmacy named, is the prescriber named, does the quoted rate hold at renewal, and what happens if a cold-chain shipment fails. Our nine-point checklist covers all of them.

Which of these two fits which patient

MyStart Health is the cheaper of the two over twelve months on our standard escalation, by $0. That gap is the starting point, not the answer — here is what each side offers that the other does not.

• Pick MyStart Health if buyers who want one price covering both molecules and both formats matters more to you than the price difference.
• Pick Gala Health if midlife-focused care with a flat rate, if you can commit for a full year is the priority.
• Neither, if you cannot get a straight answer about which pharmacy fills the prescription. That question outranks a $0 difference — see the verification walkthrough.

What each one publishes before you pay

Our disclosure score measures how much a program tells you up front — pricing at every dose, the pharmacy behind it, the terms. It is not a safety rating and not a recommendation, and the full formula and dataset are published so you can recompute it.

What this comparison deliberately leaves out

Service quality, shipping reliability and clinical depth are not scored here, because we do not hold measurements of them that we would defend in public. Both programs should be read alongside their full reviews and, where our sources disagree on price, the conflict notes on those pages.

MyStart Health vs Gala Health: where the money separates

A single annual figure hides when the gap opens. This is the same two programs tracked month by month through a first year, so you can see whether the difference is front-loaded during titration or accumulates quietly at maintenance.

Across the year the gap reaches $0, roughly 0% of the larger program's twelve-month total and about 0.0 months of therapy at the cheaper rate.

Does MyStart Health vs Gala Health change at higher tirzepatide doses?

Both programs hold one price at every strength, so the ranking here does not change with your dose. Whatever you maintain on, the gap stays the same shape.

MyStart Health and Gala Health plans, membership and prepaid terms

Only Gala Health publishes a discounted prepaid rate ($149 on its 12-month plan). MyStart Health does not, which means less commitment risk and less discount. If you are still establishing tolerance, the absence of a lock-in is worth something.

Neither program charges a separate recurring membership on top of the medication, so the advertised figure and the figure you pay are the same thing.

MyStart Health vs Gala Health on format and state availability

On delivery format they differ: MyStart Health offers sublingual that Gala Health does not. Format matters most to patients with genuine injection anxiety; note that published bioavailability evidence for compounded oral and sublingual preparations is limited, and any program selling them should be able to say what supports the claim.

Both publish comparable state coverage, so availability is unlikely to decide this for you — but confirm at checkout regardless, because service maps change without notice.

MyStart Health vs Gala Health: which discloses more

On disclosure they are close — 85/100 against 85/100 — so neither wins the argument by publishing more. Where two programs disclose similarly, the deciding questions become the ones neither publishes: renewal pricing, cold-chain failure policy, and whether a clinician will actually decline to prescribe when the history warrants it.

Switching between MyStart Health and Gala Health

If you are already with Gala Health and considering the move, the arithmetic is $0 over a year, or roughly 0.0 months of therapy at the cheaper program's maintenance rate. Set that against two real switching costs: a gap in supply while a new intake is reviewed, and the possibility that the new prescriber restarts titration rather than continuing you at your current dose. Ask about dose continuation in writing before you cancel anything, because a month at 2.5 mg is a month of lost progress that no price difference recovers.

MyStart Health vs Gala Health at every maintenance dose

The headline comparison assumes a 10 mg maintenance dose. Your prescriber may not land you there. This is the same comparison run at all six strengths, so you can find the row that matches your likely outcome rather than ours.

MyStart Health is cheaper at every maintenance dose, so this comparison does not turn on where you settle. The decision moves to what else differs: disclosure, formats, commitment terms and state coverage.

MyStart Health vs Gala Health by what you are optimizing

• Lowest possible total cost: MyStart Health, at $3,588 over a first year.
• Budget certainty: neither has an advantage — both use the same pricing model.
• Verifiability before you pay: level — both disclose the same amount against our criteria.
• Avoiding a commitment: MyStart Health, which does not require a prepaid term for its published rate.
• Regulatory status: both dispense compounded preparations, which are not FDA-approved and are not reviewed by FDA before marketing.

MyStart Health vs Gala Health over three years

Tirzepatide behaves like maintenance therapy: the withdrawal evidence shows substantial regain after stopping, so the honest planning horizon is years rather than months. Held at a 10 mg maintenance dose, three years costs roughly $10,764 with MyStart Health and $10,764 with Gala Health — a difference of $0. That is the number worth deciding on, not the first invoice.

Neither figure should be treated as fixed. Pricing in this market has moved repeatedly, and programs rarely notify existing patients when a cheaper tier appears. Re-run this comparison annually at your actual maintenance dose.

MyStart Health vs Gala Health: what neither comparison table can tell you

Shipping reliability, how fast a clinician actually replies, whether a dose adjustment takes two days or two weeks, and what happens when a cold-chain shipment fails. These decide satisfaction more than price does, and we hold no measurements of them we would defend, so they are absent from every figure above rather than estimated. Read both program reviews and, if you can, ask a current patient of each.

The one proxy worth using is what each publishes before it has your money. A program that states its price at every dose, names its pharmacy and puts its cancellation terms in writing has already told you something about how it will behave when there is a problem — which is why the disclosure comparison above sits alongside the price comparison rather than beneath it.

Running this comparison again later

Both prices carry a verification date and both will change. Programs do not notify existing patients when a competitor drops below them, and several tracked programs have moved pricing more than once in the past year. Re-run this at your actual maintenance dose annually with the projector, and treat any figure older than a month as needing a re-check before you act on it.

MyStart Health vs Gala Health: what patients get wrong most often

Four mistakes recur, and all four are expensive. Judging the drug on the first month, when the starter dose is not a treatment dose and a flat scale predicts nothing. Comparing programs on the advertised price, which describes four weeks of a twelve-month course. Treating a plateau as failure rather than as the expected shape of the trial curves. And stopping for cost without pricing the market first, when the spread between the cheapest and dearest route to the identical molecule runs from $133 to $399 a month at entry.

The fifth, less common but more serious, is buying outside the licensed channel because a price looked unbeatable. Research-labelled peptide sold without a prescription is a different market with no clinical oversight and no accountability if something goes wrong, and the disclaimer that it is not for human consumption exists so the seller can say you were told.

MyStart Health vs Gala Health: the three-year view

Current evidence treats obesity pharmacotherapy as ongoing while it remains effective, tolerated and appropriate, and the withdrawal data show substantial regain after stopping. That makes three years a more honest planning horizon than twelve months. At the cheapest tracked route, holding a 10 mg maintenance dose for three years costs roughly $7,164; at the dearest compounded route it is several times that for the same molecule. Deciding on a first-month price is deciding on the least representative number available.

MyStart Health vs Gala Health: what would change this page

New trial evidence, a change in the labelling, a shift in the compounding framework, or a correction from a reader. Clinical statements here follow the prescribing information and the published trial program; price figures carry a verification date and sit in a downloadable dataset. Where the evidence is genuinely limited — long-term data beyond the trial horizon, bioavailability of compounded oral preparations, the human relevance of the rodent thyroid finding — this site says so rather than filling the gap with confident language, and updates rather than defends when better evidence arrives.